Free Trial
→ Is this Elon’s true agenda? (From Altimetry) (Ad)

NextCure Q2 2023 Earnings Report

NextCure logo
$0.80 +0.01 (+0.73%)
As of 01/31/2025 04:00 PM Eastern
Earnings HistoryForecast

NextCure EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.60
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

NextCure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NextCure Announcement Details

Quarter
Q2 2023
Date
8/3/2023
Time
N/A

Conference Call Resources

Powered by Quartr

NextCure Earnings Headlines

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
January 10, 2025 | globenewswire.com
NextCure stock hits 52-week low at $0.99 amid market challenges
December 18, 2024 | investing.com
Is this Elon’s true agenda?
All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors have all turned to my business partner and I for our thoughts on the market. And with every investor in America wondering what Elon is going to do now that he's in Washington, this is what we tell them
February 1, 2025 | Altimetry (Ad)
NextCure Announces Acceptance of IND Application for LNCB74
December 10, 2024 | globenewswire.com
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
November 26, 2024 | globenewswire.com
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
November 19, 2024 | globenewswire.com
See More NextCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email.

About NextCure

NextCure (NASDAQ:NXTC), a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

View NextCure Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles